<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04916067</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY02000875</org_study_id>
    <nct_id>NCT04916067</nct_id>
  </id_info>
  <brief_title>Stoma Closure and Reinforcement Trial ll</brief_title>
  <acronym>SCAR-ll</acronym>
  <official_title>Stoma Closure and Reinforcement (SCAR)-II Trial: A Single Center Pilot Study of the Safety of a Mesh Reinforcement of Ileostomy Closure to Prevent Hernia Formation in Inflammatory Bowel Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Becton, Dickinson and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hernia formation at sites of ostomy closure is a common complication. The investigator&#xD;
      believes that using evidence based hernia repair techniques as a preventive measure during&#xD;
      closure of ostomies will reduce the incidence of hernia formation. In this trial, the&#xD;
      investigator will pilot a novel technique of monofilament bioresorbable mesh reinforcement of&#xD;
      the abdominal wall defects that remain after closure of an ileostomy to evaluate for safety&#xD;
      and begin to evaluate the effectiveness compared to standard techniques.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2021</start_date>
  <completion_date type="Anticipated">June 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Modified Simon-Two Step. An initial cohort of 5 patients will be enrolled and treated sequentially with 30 day follow-up. If stopping criteria are not met, the cohort will be expanded to an additional 15 patients followed concurrently for the duration of the study period</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of wound occurrences</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of wound occurrences (defined as superficial surgical site infection [s-SSI], deep surgical site infection [d-SSI], organ space surgical site infection [O-SSI], dehiscence, and seroma formation) at 30 days, with particular attention to wound occurrences requiring procedural intervention, including but not limited to, operative debridement, radiographically guided drain placement, or excision of the mesh will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of hernia formation</measure>
    <time_frame>30 days, 6 months</time_frame>
    <description>The incidence of hernia formation at the ileostomy site on a prospective basis at 30 days and at 6 months from the date of ileostomy closure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life after mesh implantation</measure>
    <time_frame>30 days, 6 months</time_frame>
    <description>Patient will be evaluated with regards to their quality of life outcomes the PROMIS SF 2.0, Ability to Participate in Social Roles and Activities, instrument at 30 days and 6 months from the date of ileostomy closure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel Function after mesh implantation</measure>
    <time_frame>30 days, 6 months</time_frame>
    <description>Patient will be evaluated with regards to their bowel function using the Colorectal Functional Outcome (COREFO) instrument at 30 days and 6 months from the date of ileostomy closure.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ileostomy - Stoma</condition>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing mesh implantation during ileostomy closure to reinforce the abdominal wall</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mesh Implantation</intervention_name>
    <description>Implantation of Phasixâ„¢ Soft Mesh - a knitted monofilament mesh scaffold using Poly-4-hydroxybutyrate (P4HB), a biologically derived material - to prevent hernia formation</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18years.&#xD;
&#xD;
          2. Patient is undergoing closure of loop ileostomy.&#xD;
&#xD;
          3. Patient has a diagnosis of Inflammatory bowel disease treated with resection and&#xD;
             diverting loop ileostomy.&#xD;
&#xD;
          4. Patient has been evaluated by a qualified surgeon and found to be a suitable candidate&#xD;
             for surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pre-existing systemic infection at the time of ileostomy takedown&#xD;
&#xD;
          2. Cirrhosis, chronic renal failure requiring dialysis, or collagen disorder&#xD;
&#xD;
          3. Previous abdominal hernia repair with mesh placement&#xD;
&#xD;
          4. Concurrent surgical procedures in addition to closure of diverting loop ileostomy&#xD;
&#xD;
          5. Ileostomy closure not completed through the previous stoma site (i.e. those requiring&#xD;
             exploratory laparotomy for closure)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Z Wilson, MD, Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew Z Wilson, MD, Msc</last_name>
    <phone>603-650-8113</phone>
    <email>Matthew.z.wilson@hitchcock.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Matthew Z Wilson, MD, MSc</last_name>
      <phone>603-650-8113</phone>
      <email>matthew.z.wilson@hitchcock.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Goldwag JL, Wilson LR, Ivatury SJ, Pauli EM, Tsapakos MJ, Wilson MZ. Stoma closure and reinforcement (SCAR): A study protocol for a pilot trial. Contemp Clin Trials Commun. 2020 Jun 9;19:100582. doi: 10.1016/j.conctc.2020.100582. eCollection 2020 Sep.</citation>
    <PMID>32577580</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 1, 2021</study_first_submitted>
  <study_first_submitted_qc>June 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>Matthew Z. Wilson</investigator_full_name>
    <investigator_title>Assistant Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>ileostomy</keyword>
  <keyword>hernia</keyword>
  <keyword>inflammatory bowel disease</keyword>
  <keyword>IBD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

